Plain-English translation of NCT06084962 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new type of treatment called DeepTag-GPRC5D CAR-T cells for multiple myeloma patients whose cancer has come back or stopped responding to previous medications. The treatment works by taking your own immune cells, modifying them in a lab to better recognize and fight your cancer cells, and then giving them back to you. Researchers want to understand how well and how safely this medication works in patients who have already tried at least three other treatment options.
Multiple myeloma can become resistant to standard treatments, leaving patients with few good options. This trial exists to see whether this new approach—using your own modified immune cells—can help patients whose cancer has stopped responding to earlier therapies.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the DeepTag-GPRC5D CAR-T cell treatment in doses that start low and gradually increase. Your own immune cells will be collected and sent to a laboratory where they are modified to fight your cancer. You will return for infusions of these modified cells and regular clinic visits to have your blood tested and to be checked for any side effects. The study will follow you for several months to evaluate how well the treatment works and to watch for both common and rare complications.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
He Huang
Collaborators
Yake Biotechnology Ltd.
Enrollment target
~40 participants
Started
October 2023
Primary completion
October 2026
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in October 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
He Huang, MD
Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.